Ultra rapid lispro (URLi) shows faster pharmacokinetics and reduces postprandial glucose excursions versus Humalog® in patients with type 2 diabetes mellitus in a randomized, controlled crossover meal test early-phase study.

Jennifer Leohr Christof KazdaRong LiuShobha ReddyMary Anne DellvaMark MatzopoulosMei Teng LohThomas HardyOliver KleinChristoph Kapitza

Published in: Diabetes, obesity & metabolism (2021)

URLi demonstrated accelerated insulin lispro absorption and greater postprandial glucose reduction at different meal-to-dose timings compared with Humalog and was well tolerated in patients with T2D.

Keyphrases

blood glucose
glycemic control
open label
type diabetes
placebo controlled
double blind
blood pressure
high resolution
randomized controlled trial
adipose tissue
weight loss
skeletal muscle
loop mediated isothermal amplification
quantum dots